
Ooh, Aah, Ouch? Billion-$ Market Feels Your Pain
There were 1,552 brands -including Volini, Omnigel, Dolo and Saridon -to tackle the twinges in 2020; now, there are 2,771.
Consumers are more attentive to alleviating any pain on a more immediate basis, said Shivam Puri, managing director at Cipla Health, which sells the biggest rubefacient brand, Omnigel. Rubefacient are gels and creams for topical application. "Rise of urbanisation and increase in chronic illnesses have led to the need for faster, more convenient formats that are accessible across platforms," said Puri. This is despite medical professionals advising caution on random use of painkillers.
The pain relief category is often lifestyle-driven in urban markets, especially with gym and sports injuries. As a result, the market for analgesics (pain relief medication) and rubefacient more than doubled to Rs 15,905 crore as of May this year, from Rs 6,820 crore as of May 2020, growing at a compounded annual rate of 18%. This is three times faster than overall over-the-counter market growth, which rose at 6% CAGR to Rs 80,000 crore.
Analgesics account for 75% of the pain medication market and within analgesics, paracetamol is the biggest contributor, according to data from market researcher PharmaTrac.
Covid has changed Indians' views on pain management, said Sandeep Verma, head for consumer health business for South Asia at Bayer Pharmaceuticals, which sells Saridon. "A lot of Indians view taking pain relief medication as a sign of weakness or worry about becoming dependent on it. Covid made many of us more aware of how stress, exhaustion, and even mild but recurring pain can chip away at our wellbeing and productivity," he said. "More people are starting to understand that living with untreated pain impacts their quality of life."
Experts said pain management medications are also used to treat inflammation and adjacent issues, widening the need for the pills.
"The analgesic segment that is dominated by paracetamols has been growing at a steady rate of 10%. This is because paracetamol medications are taken alongside other conditions that could include arthritis, any other bacterial or viral infection," said Sheetal Sapale, vice president, commercial, at PharmaTrac.
Nitin Kumar Sinha, consultant physician at Mumbai-based WeCare Wellness, said lifestyle-related problems - including rising stress levels, lack of sleep and increasing obesity - are reasons for increasing demand for pain medications.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Hindu
2 hours ago
- The Hindu
Leaders hail work of visionary scientist M.S. Swaminathan
The immunisation programme led by the country's first Health Minister, Rajkumari Amrit Kaur, and the Green Revolution initiated by M.S. Swaminathan were the reasons for the decrease in the death rate in India, former West Bengal Governor Gopalkrishna Gandhi said in New Delhi on Wednesday (August 6, 2025). Speaking at the launch of The Man Who Fed India, a biography of Dr. Swaminathan by the Singapore-based author Priyambada Jayakumar, Mr. Gandhi said three English words known by all farmers in the country was 'Swaminathan Farmer Commission'. Mr. Gandhi said Dr. Swaminathan had been part of the group of scientists around the world who stood for humanity and nuclear disarmament. 'Swaminathan's works for agriculture has given India's farmers a life,' Mr. Gandhi said. In a panel discussion that followed the book release, Shashi Tharoor, MP, said Dr. Swaminathan worked at a time when the memories of Bengal famine were haunting the country. 'International contacts' Former Planning Board Deputy Chairman Montek Singh Ahluwalia said Dr. Swaminathan revolutionised the country's agriculture through his international contacts. DMK leader Kanimozhi said Dr. Swaminathan's works for empowering women and ensuring ecologically friendly agriculture practices were not discussed the way it deserved.


Time of India
2 hours ago
- Time of India
Prostate health in focus as BPH drug demand rises in Gujarat
Ahmedabad: The sale of drugs used to treat benign prostatic hyperplasia (BPH)—a non-cancerous enlargement of the prostate gland—has surged by 70% over the past four years, indicating a significant rise in cases across the state. According to data from Pharmarack, the moving annual total (MAT) for BPH drugs was Rs 55.24 crore in June 2021, which rose to Rs 93.93 crore in June this year. The MAT for the overall urology segment also saw a 42% increase, from Rs 115.22 crore to Rs 164.2 crore during the same period. You Can Also Check: Ahmedabad AQI | Weather in Ahmedabad | Bank Holidays in Ahmedabad | Public Holidays in Ahmedabad "BPH affects a significant portion of men aged 50 and above, causing urinary difficulties and impacting quality of life. While the condition has always existed, the sharp rise in diagnosed cases and medical interventions reflects broader trends," said a pharmaceutical distributor who requested anonymity. Industry sources said that pharma companies have improved drug delivery through fixed-dose combinations, leading to better patient compliance and outcomes. The most common prescriptions now include alpha-blockers and 5-alpha-reductase inhibitors, which help alleviate symptoms and slow further prostate growth, Pharmarack data indicated. According to urologists in Ahmedabad, men are increasingly addressing symptoms of an enlarged prostate rather than ignoring them. The stigma around men's urological health is gradually diminishing, especially in urban and semi-urban areas. Dr Rohit Bhattar, a uro-onco surgeon at a city-based private hospital, said, "There has been a significant rise in BPH cases over the past decade. While traditionally considered a disease of old age, we are now seeing some patients even under the age of 50, often due to other health conditions and lifestyle factors. Greater awareness today also plays a role compared to a decade ago." While metros and Tier-I cities initially drove demand for BPH drugs, pharmaceutical industry sources report that Tier-II cities and rural areas are now seeing growing traction. Dr Hemang Bakshi, another uro-onco surgeon, noted, "The rise in drug sales must be viewed in the context of increased life expectancy. Medications are often prescribed to maintain or enhance prostate function over time. Since onset typically occurs around the age of 60, patients may remain on treatment for several years. This extended treatment duration is a contributing factor. We've certainly seen a decadal rise in the incidence of the condition. " Experts say improvements in healthcare access and preventive diagnostics in Gujarat have made a noticeable impact. Routine check-ups, ultrasounds, and PSA tests are increasingly being used to detect prostate issues at earlier stages.


Time of India
3 hours ago
- Time of India
6 PHED engrs served notice over 150 crore tubewell scam in Jalore
Jaipur: Public health engineering department (PHED) has issued notices to six engineers of the department, including a retired engineer, for alleged involvement in a scam of Rs 150 crore. Officials said these engineers reportedly gave Operations and Maintenance (O&M) tenders to two firms for more than 900 tubewells in Jalore district when they were entitled to O&M of only 20 tubewells. "We took up the issue with PHED minister Kanhaiya Lal Choudhary. Following his instructions, we are going to take major steps against these accused engineers. We will also lodge complaints with police in this regard," disclosed a senior PHED official Wednesday. An official of the department claimed that the accused—then executive engineers Umesh Kumar Meena, Shyam Bihari Bairwa, Jitendra Trivedi, Hemant Kumar Bairwa, Ashish Dwivedi (retd), and Hemant Kumar Vaishnav—gave the work orders for O&M of 981 tubewells on Aug 12, 2022, to two firms—MM Construction and MS Raj Enterprise. "In gross violation of norms, the then superintendent engineer of the circle issued this work order for 981 tubewells. The two firms should have got work orders for only 20 tubewells. For the last three years, the department is unnecessarily wasting money on O&M expenditure for such a huge number of additional tubewells. The department has also blacklisted the two firms," the official added. Investigation revealed that PHED bore O&M expenditure for around 3,500 tubewells in Jalore for the last three years, when the actual number of tubewells of the department in the district was only close to 1,500.